Genmab — August 2018
-
Sequencing Through Multiple Lines of Therapy https://www.onclive.com/peer-exchange/myeloma-next-gen-regimens/sequencing-through-multiple-lines-of-therapy
-
Daratumumab in Primary Effusion Lymphoma
https://www.nejm.org/doi/full/10.1056/NEJMc1806295 -
Is immunotherapy cost-effective? http://www.oncologytube.com/video/is-immunotherapy-cost-effective/10004937
-
Ved det ikke, men fandt dette: "a main concern, which is the possibility of CAR T–BCMA–induced immune editing whereby residual MM cells decrease their BCMA expression following CAR T cell infusion, enabling immune evasion. Therefore, using a dual- or even triple-targeting CAR could potentially overcome this problem and enhance the response rate to CAR T cell therapy"
-
-
Det må man sige.
-
Nu hvor du er på Helge. Hvor stor en sandsynlighed vurderer du der er, på at MAIA fejler?
-
Du er godt nok usikker i din Investor13 - synes du spørger om det ret ofte. Har du smidt en for stor del af din portofølge i GEN?
-
i din sag *
-
ift. hvad din risikovillighed kan bære
-
ja, ca. 50%. Men der fordi jeg tror på casen. Spekulerer bare om jeg skal reducere snart, inden MAIA data. Selvom jeg klart mest hælder til succes.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind